Second malignancy after treatment of acute promyelocytic leukemia: Experience of GIMEMA trials [6]

Blood

Volumn 100, Issue 4, 2002, Pages 1514-1515

  Pagano, Livio ^a   Pulsoni, Alessandro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DAUNORUBICIN; EPIPODOPHYLLOTOXIN; GYRASE INHIBITOR; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE;

ACUTE LEUKEMIA; ADULT; AGED; CANCER INCIDENCE; CANCER RECURRENCE; CLINICAL TRIAL; HUMAN; INTESTINE CANCER; KIDNEY CANCER; LETTER; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SECOND CANCER; THYROID CANCER;

EID: 0037103313     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0886     Document Type: Letter

References (7)

1. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: An emerging problem
2. Acute promyelocytic leukemia: Clinical aspects and results of treatment in 62 patients
3. Event free survival (EFS) duration in newly diagnosed acute promyelocytic leukemia (APL) is favorably influenced by induction treatment with idarubicin alone: Final results of the GIMEMA randomized study "LAP0389" comparing IDA vs IDA+ARA-C in newly diagnosed APL
4. Molecular remission in PML/RAR alphapositive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy: Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups
5. Cancer in Italy: Incidence data from Cancer Registries
6. Second cancers and other late side effects of cancer treatment: A review
7. Therapy-related acute leukemia